Medical device companies – including Sientra, Endologix and Invacare – won loans from the US government’s Paycheck Protection Program, intended to protect jobs during the coronavirus pandemic. In total, nearly 1,400 device makers collected as much as $1.6bn, according to a Medtech Insight analysis of PPP data.

Driven by increasingly cost-conscious payers, health care is shifting from a volume-based model to “value-based care,” now the latest buzzword. In response, the medical device industry has started employing new commercial strategies.

This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.

German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.